Fatty acid scavenging enables cancer escape from KRAS inhibition

KRAS inhibitor-resistant cancer cells overcome treatment by utilizing the ADGRB1 receptor to drive macropinocytosis-mediated fatty acid scavenging and beta-oxidation, a metabolic adaptation that sustains bioenergetics independently of canonical KRAS signaling and can be reversed by disrupting the ADGRB1-PI3Kγ pathway.

The Gist

The Big Picture: The "Unbeatable" Cancer Escape Plan

Imagine cancer cells as a group of thieves trying to rob a bank (the body). For years, doctors have had a very specific "security system" called KRAS inhibitors. These drugs are designed to cut the power to the thieves' main control room (the KRAS protein), effectively freezing them in place so they can't grow or spread.

For a long time, scientists thought that if you cut the power to the control room, the thieves would just starve and die. But this new research discovered something surprising: The thieves didn't just sit there; they found a secret backdoor and a new way to eat.

Even when the main control room is shut down, these cancer cells found a way to survive by scavenging food from their neighbors. This paper explains exactly how they do it and, more importantly, how we can finally catch them.

---

The Story in Three Acts

Act 1: The Starvation Trap (and the Cheat Code)

When doctors give patients KRAS inhibitors, the cancer cells are supposed to starve because they can't make their own energy.

• The Normal Cells: Think of sensitive cancer cells as people who only eat food they cook themselves. If you ban their kitchen (KRAS), they starve.
• The Resistant Cells: The "bad" cancer cells are like survivalists. They realized, "Hey, we don't need to cook! We can just raid the fridge next door."

The paper found that these resistant cells are incredibly good at scavenging fat (fatty acids) from the surrounding fat tissue in the body. They don't just eat a little bit; they gorge themselves on fat to keep their engines running, completely ignoring the fact that their main control room is broken.

Act 2: The "Big Drink" (Macropinocytosis)

How do they get this fat? They use a process called macropinocytosis.

• The Analogy: Imagine a normal cell is a person using a straw to sip a drink. A resistant cancer cell is like a person who grabs a giant bucket and dumps the whole ocean into their mouth.
• They literally engulf huge chunks of their environment, including fat droplets released by nearby fat cells (adipocytes). This "big drink" provides them with the fuel they need to keep growing, even while the KRAS drug is trying to stop them.

Act 3: The Secret Switch (ADGRB1)

So, what turns on this "Big Drink" mode? The researchers found a specific switch on the cancer cell's surface called ADGRB1.

• The Metaphor: Think of ADGRB1 as a master key or a remote control. When the main KRAS power is cut, this remote control activates a different, hidden pathway (involving a protein called PI3Kγ).
• This hidden pathway tells the cell: "Ignore the broken main engine! Start the scavenging mode! Grab all that fat!"
• Once this switch is flipped, the cancer cells become independent of the KRAS protein. They don't need the drug to work anymore; they just need the fat.

The Solution: How to Stop the Escape

The most exciting part of this paper is the solution. The researchers realized that if you block this "scavenging switch," the cancer cells lose their superpower.

• The Strategy: If you give the patient the KRAS inhibitor (to break the main control room) AND a drug that blocks the ADGRB1 switch (to stop the scavenging), the cancer cells are trapped. They can't cook their own food, and they can't steal food from the neighbors.
• The Result: In the lab and in mice, this combination therapy caused the resistant tumors to shrink and die. It turned an unbeatable enemy back into a vulnerable one.

Why This Matters for Patients

1. It explains the failure: Many patients with pancreatic cancer (and other cancers) stop responding to KRAS drugs after a while. This paper explains why: the cancer isn't "fixing" the broken control room; it's just switching to a different way of eating.
2. It offers a new weapon: We don't need to invent a whole new drug from scratch. We can use existing drugs that block the scavenging pathway (like a PI3Kγ inhibitor) and combine them with the current KRAS drugs.
3. It works across the board: This trick isn't just for one type of cancer. The researchers found this same "scavenging switch" in pancreatic, colon, and uterine cancers. It's a universal cheat code that many cancers use.

The Bottom Line

Cancer is a master of adaptation. When we block one door, it finds a window. This paper shows us that the window is a "fat scavenging" system controlled by a switch called ADGRB1. By closing that window, we can finally stop the cancer from escaping our best drugs.

Technical Summary

1. Problem Statement

Oncogenic KRAS mutations drive nearly 90% of pancreatic ductal adenocarcinoma (PDAC) cases and are prevalent in other cancers. While recent structure-guided inhibitors (e.g., sotorasib, adagrasib, MRTX1133, HRS-4642) targeting specific KRAS mutants (G12C, G12D) have shown clinical promise, acquired drug resistance remains a major barrier to long-term efficacy.

• The Gap: The molecular and metabolic mechanisms allowing cancer cells to survive and proliferate despite the effective suppression of canonical KRAS signaling (ERK/AKT pathways) are poorly understood.
• The Question: How do KRAS-inhibited cancer cells rewire their metabolism to maintain bioenergetics and evade cell death?

2. Methodology

The study employed a multi-disciplinary approach combining cell biology, metabolomics, genetics, and clinical correlation:

• Model Systems:
  • In Vitro: Human PDAC cell lines (AsPC-1, PANC-1, SW1990, etc.) and patient-derived organoids (PDOs) stratified into KRAS inhibitor-sensitive (KS) and resistant (KR/AR) groups. Resistant models were generated via intrinsic selection or long-term drug exposure (acquired resistance).
  • In Vivo: Orthotopic mouse models using KRAS-mutant PDAC cells (KC6141) with inducible gene ablation (CPT1, ADGRB1).
  • Clinical: Analysis of human PDAC surgical specimens (n=42) and paired pre/post-treatment colorectal cancer samples.
• Metabolic Profiling:
  • Transcriptomics: RNA-seq to identify pathway alterations in resistant vs. sensitive cells.
  • Metabolomics: LC-MS/MS for acyl-CoA species; Stable isotope tracing ($^{13}$C-palmitic acid) to track fatty acid oxidation (FAO) flux into the TCA cycle.
  • Imaging: Mass Spectrometry Imaging (AFADESI-MSI and MALDI-MSI) to visualize lipid and metabolite distribution in tumor tissues.
• Functional Assays:
  • Macropinocytosis (MP): Quantified via uptake of high-molecular-weight dextran (TMR-DEX) and fluorescent fatty acids (BODIPY-PA).
  • Respiration: Seahorse XF analysis (OCR) and ATP production assays.
  • Genetic/Pharmacological Perturbation: CRISPR/Cas9 or shRNA-mediated knockdown of ADGRB1, CPT1, PI3K$\gamma$, and FASN; treatment with specific inhibitors (IPI549 for PI3K$\gamma$, EIPA for MP, etomoxir for CPT1).
  • Co-culture: Adipocyte (3T3-L1) co-culture systems to test lipid transfer.

3. Key Contributions & Findings

A. Metabolic Rewiring: FAO as a Survival Mechanism

• Observation: KRAS inhibitor-resistant (KR/AR) cells maintain mitochondrial bioenergetics and proliferation even when canonical KRAS signaling (pERK, pAKT) is suppressed.
• Mechanism: Unlike sensitive cells, resistant cells upregulate Fatty Acid Oxidation (FAO). They maintain high levels of palmitoyl-CoA and show increased flux of exogenous fatty acids into the TCA cycle (citrate, $\alpha$-KG, succinate).
• Dependency: Resistant tumors rely heavily on CPT1 (Carnitine Palmitoyltransferase 1) for mitochondrial fatty acid import. Ablation of CPT1 sensitizes resistant tumors to KRAS inhibition, whereas it has minimal effect on sensitive tumors.

B. Source of Fatty Acids: Macropinocytosis of Adipocyte Lipids

• Discovery: Resistant cells do not primarily rely on de novo lipogenesis (FASN inhibition did not rescue sensitivity). Instead, they scavenge extracellular fatty acids.
• Mechanism: Resistant cells exhibit hyperactive Macropinocytosis (MP), engulfing extracellular lipids released by surrounding adipocytes.
• Evidence:
  • Co-culture with adipocytes showed AR cells acquired significantly more lipids than KS cells.
  • In mice with adipocyte-specific deletion of ATGL (Adipose Triglyceride Lipase), AR tumor growth was severely restricted, confirming dependence on adipocyte-derived lipids.
  • Inhibition of MP (EIPA) blocked lipid uptake and restored drug sensitivity.

C. The Signaling Axis: ADGRB1-PI3K$\gamma$-PAK1

• The Driver: The study identified ADGRB1 (BAI1), an adhesion G-protein coupled receptor (GPCR), as the master regulator of this resistance.
• Signaling Pathway:
  • In resistant cells, ADGRB1 is upregulated and activates G$\alpha$12/13.
  • This triggers a non-canonical PI3K$\gamma$-PAK1 signaling axis.
  • Crucially, this pathway is independent of PI3K$\alpha$ (the canonical KRAS effector) and NRF2.
  • ADGRB1 drives the phosphorylation of PAK1 at Serine 144 (pS144-PAK1), which sustains macropinocytosis and FAO.
• Validation: Knockdown of ADGRB1 or inhibition of PI3K$\gamma$ (using IPI549) abolished MP, reduced FAO, and sensitized resistant cells to KRAS inhibitors.

D. Clinical Relevance

• Human Tissues: High expression of ADGRB1, PI3K$\gamma$, pS144-PAK1, and CPT1 correlates with intrinsic resistance to KRAS inhibitors in human PDAC organoids and surgical specimens.
• Prognosis: Patients with high ADGRB1 or pS144-PAK1 expression have significantly poorer overall survival.
• Acquired Resistance Case: A patient with colorectal cancer who developed resistance to the KRASG12D inhibitor QLC1101 showed a shift from canonical signaling suppression to elevated ADGRB1-PI3K$\gamma$-pS144-PAK1 signaling and FAO enzymes.

4. Results Summary

1. Metabolic Shift: KRAS inhibition forces sensitive cells to stop FAO, but resistant cells adapt by scavenging exogenous fatty acids via macropinocytosis to fuel FAO.
2. Adipocyte Interaction: The tumor microenvironment (specifically adipocytes) provides the lipid fuel; blocking adipocyte lipolysis (ATGL KO) starves resistant tumors.
3. Novel Pathway: ADGRB1 activates PI3K$\gamma$ (not PI3K$\alpha$) to phosphorylate PAK1 at S144, driving macropinocytosis independently of KRAS.
4. Therapeutic Synergy: Combining KRAS inhibitors with PI3K$\gamma$ inhibitors (IPI549) or ADGRB1 ablation induces synergistic tumor regression in resistant models, whereas these combinations have little effect on sensitive models.

5. Significance

• Mechanistic Insight: This study reveals a previously unknown "metabolic escape route" where cancer cells bypass KRAS dependency by hijacking adipocyte-derived lipids via macropinocytosis.
• Biomarker Potential: ADGRB1 and pS144-PAK1 serve as predictive biomarkers for KRAS inhibitor resistance and poor prognosis.
• Therapeutic Strategy: It proposes a novel combinatorial therapy: KRAS inhibitor + PI3K$\gamma$ inhibitor (or ADGRB1 targeting). This approach specifically targets the adaptive metabolic program of resistant cells, potentially overcoming one of the biggest hurdles in KRAS-driven cancer treatment.
• Broader Impact: The findings suggest that the tumor microenvironment (adipose tissue) plays a critical, active role in drug resistance, highlighting the need to target stromal-tumor metabolic crosstalk.

Conclusion: The paper demonstrates that KRAS inhibitor resistance is driven by an ADGRB1-mediated, PI3K$\gamma$-dependent metabolic adaptation that allows cancer cells to scavenge fatty acids from adipocytes, sustaining mitochondrial energy production and proliferation despite the loss of canonical KRAS signaling. Targeting this axis offers a promising strategy to restore drug sensitivity.